Introduction
============

Leber congenital amaurosis (LCA; OMIM [204000](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=204000)) is a term used to describe a heterogenous and typically autosomal recessive group of inherited retinal dystrophies characterized by: severe visual impairment at birth; normal-appearing retina; and profoundly reduced electroretinogram. Thirteen genes have been associated with LCA**:** aryl hydrocarbon receptor interacting protein-like 1 (*AIPL1)* \[[@r1]\], crumbs homolog 1 (*CRB1)* \[[@r2]\], cone-rod homeobox (*CRX)* \[[@r3]\], guanylate cyclase 2D (*GUCY2D*; *RETGC1*) \[[@r4]\], inosine monophosphate dehydrogenase 1 (*IMPDH1)* \[[@r5]\], Leber congenital amaurosis 5 (*LCA5)* \[[@r6]\], lecithin retinol acyltransferase *(LRAT)* \[[@r7]\], nephronophthisis 6 (*NPHP6; CEP290*) \[[@r8]\], retinol dehydrogenase 12 (*RDH12)* \[[@r9]\], retinal degeneration 3 (*RD3)* \[[@r10]\], retinal pigment epithelium-specific protein 65 kDa (*RPE65)* \[[@r11]\], and retinitis pigmentosa GTPase regulator interacting protein 1 (*RPGRIP1)* \[[@r12]\], tubby like protein 1 (*TULP1)* \[[@r13],[@r14]\]. The frequency of disease-associated mutations among eight of these genes has recently been assessed in large populations of patients, using a range of technologies \[[@r15]-[@r18]\]. Many of the variations detected in these studies were only rarely observed, but nearly 100 different variations were detected in two or more unrelated LCA patients \[[@r18]\].

In one study, mutations in *GUCY2D*, *RPE65,* and *CRX* were detected in LCA patients from India, although at lower frequency than previously reported in cohorts from northern America \[[@r19]\]. In another study, mutations in *RPE65* were similarly detected in a smaller proportion of LCA patients from India than in northern America \[[@r20]\]. Finally, a 2006 \[[@r10]\] study of *RD3* identified a mutation in an Indian family, but found no examples in LCA patients from northern America. Although these studies have explored the role of some previously discovered LCA genes in causing disease in patients from India, no comprehensive investigation of multiple genes has been performed on this population. We set out to determine the frequencies of mutations associated with LCA in the Indian population by testing 38 unrelated LCA patients from India for 104 previously identified mutations in eight genes. In a 2007 study \[[@r18]\] of 642 northern American LCA patients, 49 of these 104 mutations cumulatively contributed to more than 30% of LCA cases.

Methods
=======

The study received approval from the Ethical Review Board of Aravind Eye Care System in India, and the Institutional Review Board of the University of Iowa (Iowa City, IA). Informed consent was obtained from all participants. Patients were examined at the Aravind Eye Hospital (Madurai, India), a regional facility serving a large area of southern India. As such, patients and controls recruited for this study represent an unselected sampling of the South Indian population. A total of 41 unrelated individuals were enrolled in this study as probands after a diagnosis of LCA. Probands were from 6 months to 12 years of age at enrollment (mean 5.0 years SD±3.3), 24 female and 17 male, and in good health. Diagnosis of LCA was based on the following criteria: 1) severely reduced vision in both eyes that was recognized within two years of birth; 2) relatively normal appearance of the retina; 3) profoundly reduced or nonrecordable ISCEV electroretinogram; and 4) absence of symptoms that would suggest another disease. When possible, relatives were also assessed and included in the study for assessment of inheritance phase. A total of 84 family members were enrolled, this included: 74 parents (0 affected; 33 male, 41 female; mean age 32.2 years SD±7.5), and 12 siblings (2 affected, 1 female aged 2 and 1 male aged 7; 10 unaffected, 6 male, and 4 female; mean age 10.7 years SD±4.0). Although each proband was unrelated, consanguinity was identified from histories in the families of 34 of 41 probands (83%). Additionally, 25 unrelated healthy individuals were used as control study subjects.

DNA preparation
---------------

Peripheral blood (approximately 10 ml) was collected using vacutainer EDTA (EDTA) tubes (Becton-Dickinson, Franklin Lakes, NJ), and DNA was extracted by salt precipitation \[[@r21]\]. Blood samples were obtained from 41 unrelated affected individuals with LCA. However, the concentration of the DNA obtained from three of these participants was inadequate for the allele-specific ligation assay. Consequently, only 38 individuals were studied with both the allele-specific ligation assay and bidirectional sequencing of *NPHP6*, as will be described.

Allele-specific ligation assay
------------------------------

LCA-associated mutations in *GUCY2D*, *RPE65*, *CRB1*, *AIPL1*, *CRX*, *RDH12*, and *RPGRIP1* have been well characterized in northern American populations \[[@r18]\]. A total of 177 previously reported mutations in these genes were identified in a review of the literature. A multiplexed allele-specific assay was designed to detect 138 of these mutations using the SNPlex platform (Applied Biosystems, Foster City, CA). Four of the 138 probes were subsequently found to be benign polymorphisms \[[@r18]\], or evidence for disease causing status was inconclusive (RPGRIP1 ARG812GLN). These probes were therefore excluded from analysis. Of the remaining 134 plausible disease-causing alleles, technical limitations in the probe sets meant the assay was unable to reliably detect either allele for 31 single nucleotide polymorphisms (SNPs). Consequently, genotypic data from 103 SNPs were included in our analysis ([Table 1](#t1){ref-type="table"}).

###### Genotypes for deliberately assessed alleles.

  **Gene**         **Mutation**   **NL**    **Mut**   **Gene**            **Mutation**        **NL**    **Mut**   **Gene**           **Mutation**   **NL**    **Mut**             
  ---------------- -------------- --------- --------- ------------------- ------------------- --------- --------- ------------------ -------------- --------- ---------- ---- --- ---
  **Het**          **Hom**        **Het**   **Hom**   **Het**             **Hom**                                                                                                 
  *AIPL1*          VAL71PHE       38        0         0                   *GUCY2D*            MET1ILE   38        0                  0              *RPE65*   GLY40SER   38   0   0
  MET79THR         37             0         0         LEU41PHE            38                  0         0         ARG44GLN           38             0         0                   
  TRP88STOP        37             0         0         TYR173ins6tACGCCC   38                  0         0         GLY46del1G         38             0         0                   
  CYS89ARG         37             0         0         ARG313CYS           38                  0         0         ARG91GLN           38             0         0                   
  ALA197PRO        38             0         0         LEU325PRO           37                  0         0         ARG91TRP           38             0         0                   
  LYS242del3AAG    38             0         0         SER448STOP          38                  0         0         GLU102STOP         38             0         0                   
  TRP278STOP       38             0         0         ARG540CYS           38                  0         0         ARG124STOP         38             0         0                   
  LEU293PRO        38             0         0         ARG660STOP          38                  0         0         ALA132THR          37             0         0                   
  ARG302LEU        38             0         0         TYR746CYS           38                  0         0         THR162PRO          37             0         0                   
  IVS3 1G\>A       38             0         0         GLU750STOP          34                  0         0         ASN205del2aaCA     38             0         0                   
  *CRB1*           PHE144VAL      38        0         0                   ARG768TRP           38        0         0                  ARG234STOP     38        0          0        
  THR289MET        38             0         0         THR839ALA           38                  0         0         TYR239ASP          37             0         0                   
  CYS383TYR        38             0         0         LEU954PRO           38                  0         0         VAL287PHE          38             0         0                   
  CYS681TYR        38             0         0         SER981del1G         38                  0         0         TYR318ASN          38             0         0                   
  GLU710GLN        38             0         0         CYS984TYR           38                  0         0         CYS330TYR          38             0         0                   
  MET741THR        38             0         0         MET1009LEU          38                  0         0         LEU341SER          36             0         0                   
  PRO748del3cCAT   38             0         0         HIS1019PRO          38                  0         0         ALA360PRO          38             0         0                   
  ARG764CYS        38             0         0         ARG1029SER          38                  0         0         TYR368HIS          37             0         1                   
  LYS801STOP       38             0         0         GLN1036STOP         38                  0         0         ALA393GLU          38             0         0                   
  GLY827STOP       38             0         0         IVS9--2T\>A         38                  0         0         GLU417GLN          38             0         0                   
  ILE852THR        38             0         0         IVS16--4A\>T        33                  0         0         TRP460CYS          38             0         0                   
  ASN871ins1aaT    34             0         0         *NPHP6*             IVS26 c.2991+1655   38        0         0                  GLU462STOP     38        0          0        
  CYS896STOP       38             0         0         *RDH12*             THR49MET            38        0         0                  VAL473ASP      38        0          0        
  SER1025ILE       38             0         0         LEU99ILE            38                  0         0         GLY528VAL          38             0         0                   
  ILE1100ARG       38             0         0         GLY127STOP          38                  0         0         *RPGRIP1*          ASP248HIS      38        0          0        
  LEU1107ARG       38             0         0         HIS151ASP           38                  0         0         SER502ins4tcTGTC   38             0         0                   
                   LEU1107PRO     35        0         0                   SER175PRO           37        0         0                  ARG580GLY      36        0          0        
  TRP1293STOP      38             0         0         TYR194STOP          35                  0         0         GLY746GLU          38             0         0                   
  ASN1317HIS       38             0         0         ALA206ASP           38                  0         0         LEU856ins2cTT      38             0         0                   
  CYS1321GLY       35             0         0         TYR226CYS           38                  0         0         ASP877GLY          38             0         0                   
  GLU1330del1G     37             0         0         PRO230ALA           38                  0         0         GLU1279del3GAG     32             0         0                   
  IVS10--1G\>T     38             0         0         ALA269del5CCCTG     38                  0         0         IVS8--3A\>G        37             0         0                   
  *CRX*            GLU173del1G    38        0         0                   IVS5--1G\>A         38        0         0                  IVS15--1G\>A   38        0          0        
  VAL180del1G      38             0         0                                                                                        IVS16--1G\>A   38        0          0        
  TYR191del1T      38             0         0                                                                                                                                     
  TYR195STOP       35             0         0                                                                                                                                     
  GLY217del1G      35             0         0                                                                                                                                     

The presence or absence of LCA-causing alleles as assessed by SNPlex allele specific ligation assay and bidirectional sequencing (NPHP6 IVS26 c.2991+1655 only) are shown by gene. For each allele assessed, the number of proband samples identified as homozygous normal (NL), heterozygous for a disease causing allele (Mut - Het) or homozygous for a disease causing allele (Mut - Homo) are shown. Any discrepancy between the sum of these numbers and the 38 samples assayed is due to failed allele calls.

DNA sample preparation, allele-specific ligation, and post-ligation amplification were performed in 96 well plates according to the manufacturer's instructions (SNPlex, Applied Biosystems). PCR products were analyzed with a 3730 DNA sequencer and GeneMapper software (Applied Biosystems). Allele status was initially assigned using custom software developed at the University of Iowa, and allele assignments were then confirmed manually. In some cases, genotypes could not be reliably assigned because of low probe signal strength (below 500 units for both normal and mutant alleles). In total 51 of 3,914 genotypes (1.3%) were excluded for this reason.

Positive results from the allele-specific assay were verified by bidirectional sequencing of an amplimer spanning the mutation in question. Confirmed mutations were assessed in relatives of the probands to establish phase. Approximately 150 ng of each patient\'s DNA was used as template in a 30.0 µl PCR containing the following: 3.0 µl 10X buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl~2~), 9 mM of each dCTP, dATP, dGTP, and dTTP, 9 pmole of each primer (Integrated DNA Technologies, Coralville, IA), and 0.9 units of DNA polymerase (Biolase, Irvine, CA). Samples were denatured for 5 min at 94 °C and incubated for 35 cycles under the following conditions: 94 °C for 30 s, 57 °C for 30 s, 72 °C for 30 s in an MJ Research DNA thermocycler (BioRad, Waltham, MA). PCR products were purified with the QIAquick PCR purification kit (Qiagen, Valencia, CA). Sequencing was by dye-termination chemistry on an ABI 3730 DNA sequencer (Applied Biosystems), with subsequent sequence analysis using Sequencher (Gene Codes Corporation, Ann Arbor, MI).

*NPHP6* IVS26 c.2991+1655 mutation screening
--------------------------------------------

In the northern American population, the single most common LCA-associated mutation is a deletion within intron 26 of *NPHP6* (IVS26 c.2991+1655). Therefore a screen of this mutation was conducted in parallel to the SNPlex assay. The presence or absence of the c.2991+1655 mutation in intron 26 of *NPHP6* was assessed by bidirectional sequencing of genomic DNA from each unrelated affected individual. Only those also studied through the SNPlex assay (n=38) were included in this report. Reaction conditions and sequence analysis were as described in the previous section, except annealing conditions were as follows: 30 s, with 65 °C for the first cycle, reducing in temperature increments over the next nine cycles to 60 °C, followed by 25 cycles at 60 °C.

Results
=======

The presence or absence of 103 LCA-causing mutations was successfully assayed with an allele-specific ligation assay applied to 38 patients with LCA from southern India. Genotype was determined in 3,755 of 3,914 tests, giving a sensitivity of 95.9% for these alleles ([Table 1](#t1){ref-type="table"}; the 104^th^ allele was assayed only by bidirectional sequencing, please see paragraph referring to *NPHP6* below). Of these disease-causing mutations previously found in the northern American population, only one example was identified in the cohort from South India.

Patient ILCA-65--1 was homozygous for the mutation (Tyr368His TAT\>CAT) in *RPE65* ([Figure 1](#f1){ref-type="fig"}). This patient presented at the Aravind Eye Institute at 3 years of age with a history of poor vision. On examination, visual acuity was 20/80 (6/24) in the right eye and 20/200 (6/60) in the left eye. Both dark-adapted scotopic and light-adapted photopic electroretinograms were nonrecordable. At age 9, pigmentary changes were observed in the midperiphery of the the child's fundus. Unaffected parents and an affected sibling were available for study. The affected sibling was examined at 2 years of age and had visual acuities of 20/120 (6/36) in the right eye and 20/160 (6/48) in the left eye, extinguished electroretinogram responses, and pigmentary retinopathy. The presence of this mutation was confirmed with bidirectional DNA sequencing and the phase established in available samples from relatives. Both unaffected parents were found to carry a heterozygous Tyr368His mutation, while the affected sibling was homozygous for the Tyr368His mutation.

![Clinical and molecular data for patient ILCA-65--1 and family. The proband first presented for ophthalmic examination at 3 years of age. **A**: There were no recordable responses to light in the electroretinogram. Examples shown are from the left eye for a dark-adapted combined response and a light-adapted photopic response. Arrowhead points to the timing of the 10-ms bright light pulse. **B**: The family tree shows the proband (filled circle with arrow) and a sibling as clinically affected and both parents as unaffected. **C**: Bidirectional sequencing showed that the *RPE65* Tyr368His TAT\>CAT mutation was homozygous in the affected proband (S1) and affected sibling (S3), and was heterozygous in the mother (M) and father (F). Reverse strand sequence around *RPE65* Tyr368 (caNatct) is shown against an ethnic unrelated and unaffected control normal (NL).](mv-v15-1781-f1){#f1}

In one instance, a mutation detected by the allele-specific assay was not confirmed by subsequent DNA sequencing. A Glu102STOP mutation in the *RPE65* gene of one patient (ILCA-100--1) was suggested by the allele-specific assay. However, DNA sequencing showed this to be a false positive, and identified a different *RPE65* mutation that was not included on our allele-specific assay (a homozygous Tyr143Asp TAC\>GAC; [Figure 2](#f2){ref-type="fig"}). Patient ILCA-100--1 was first presented at the Aravind Eye Institute at 4 months of age with the mother's complaint that the infant was not fixating on the her face. The patient was full term at birth, with normal delivery and no remarkable antenatal or perinatal problems. At 3 years of age, the patient's examination was consistent with LCA: severe visual impairment with nonrecordable electroretinogram in both eyes, normal anterior segment, and abnormal pigmentation in all four quadrants of the fundus with mild temporal pallor of the discs in both eyes. At age 4, on a recent follow-up, the subject was found to have a visual acuity of 20/120 (6/36) with both eyes open, and has achieved otherwise normal developmental milestones. Again, family history identified consanguinity, and both unaffected parents were found to be heterozygous for the Tyr143Asp mutation.

![Clinical and molecular data for patient ILCA-100--1 and family. The proband first presented for ophthalmic examination at 4 months of age. When the proband was 3 years old **(A),** there were no recordable responses to light in the electroretinogram. Examples shown are from the left eye for a dark-adapted combined response and a light-adapted photopic response. Arrowhead marks the timing of the 10-ms bright light pulse. **B**: The family tree shows the proband (filled circle with arrow) as clinically affected, and both parents are unaffected. **C**: Bidirectional sequencing showed that the *RPE65* Tyr143Asp TAC\>GAC mutation was homozygous in the affected proband (P) and was heterozygous in the mother (M) and father (F). Reverse strand sequence around *RPE65* Tyr143 (atNacta) is shown against an ethnic unrelated and unaffected control normal (NL).](mv-v15-1781-f2){#f2}

The same cohort of 38 LCA patients were tested for the c.2991+1655 A\>G mutation in intron 26 of *NPHP6* with bidirectional DNA sequencing. No instances of this mutation were detected.

Discussion
==========

LCA is a heterogeneous condition that is responsible for severe vision loss at birth. In the past 10 years great progress has been made in identifying the genes that are responsible for this condition. Mutations in the eight genes we studied in the South Indian population account for 64% of LCA in the United States \[[@r18]\].

In the current study, we explored the role of previously discovered LCA mutations in a cohort of patients from southern India by testing for the presence of 104 previously reported mutations in eight LCA genes. While this particular set of mutations has been associated with roughly 30% of LCA cases in prior studies of patients from northern America, only one proband in the cohort from southern India (ILCA-65--1) was found to carry one of these 104 mutations previously associated with LCA.

Our SNPlex assay incidentally detected a plausible disease-causing mutation in the *RPE65* gene that was not one of the 103 alleles included in the original assay design. A homozygous Tyr143Asp mutation was identified in subject ILCA-100--1. Segregation of the mutation with disease in the family supports the Tyr143Asp mutation as the cause of disease in this subject. Although we had not previously observed Tyr143Asp in LCA, we have observed Tyr143Asp as one of the disease-causing mutations in a patient categorized as having early onset retinitis pigmentosa. The relatively good vision for an LCA patient and early pigmentary changes of ILCA-100--1 illustrate the potential for overlap in these clinical categories when the cause of disease can be traced to mutations in the same gene.

The lower prevalence of mutations in the cohort of patients from India is likely due in part to the high rate of novel mutations that are detected in LCA genes. In a prior study, 77% of disease-causing variations that were detected were only observed once \[[@r18]\]. Consequently, it is plausible that as for patient ILCA-100--1, many patients in our study have novel mutations in *GUCY2D*, *RPE65*, *CRB1*, *AIPL1*, *CRX*, *RDH12*, *RPGRIP*, or *NPHP6* that were not included in the mutation-specific assay. Alternatively, it is possible that a large proportion of LCA cases from India are caused by mutations in novel or other known LCA genes (*LCA5* or *RD3*) \[[@r10],[@r22]\]. Thus, our Indian cohort of patients may be a useful resource for identifying additional novel LCA genes or new mutations in known LCA genes. Furthermore, our research suggests that mutation-specific assays that are designed from studies of LCA patients from one ethnic population are not the most efficient approach for studying patients from different populations and ethnic backgrounds.

The value of a detailed molecular screen of LCA patients from the Indian population lies in genetic counseling, improved diagnosis and prognosis, the support this gives to gene discovery efforts, and, more recently, in identifying patients for treatment. In both families with a molecular diagnosis from this study, the mutation was in *RPE65*, so the recent success of gene therapy for *RPE65* presents a very real hope of treatment in the future that will improve the vision of these patients \[[@r23]-[@r25]\].
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